Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook.

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head, R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Ash Verma - UBS Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Omri Efroni - Oppenheimer Umer Raffat - Evercore Glen Santangelo - Jefferies Chris Schott - J.P. Morgan Yifeng Liu - HSBC Operator Hello, and welcome to the Teva Pharmaceuticals Industries Limited Q2 2024 Earnings Call.

Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call Transcript

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Olanzapine LAI (mdc-TJK) No PDSS* observed after completion of c.95% of the targeted injections for submission Full phase 3 safety results on track for H2 2024 Positive phase 3 efficacy results have already been announced in May 2024 (read the full PR) UZEDY® Reaffirming revenue guidance for 2024: c.$80 million Exploring an additional indication for UZEDY® for the treatment of Bipolar I Disorder in adults ACCESS HERE THE FULL PRESS.

Medincell's partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?

On Wednesday, Teva Pharmaceutical Industries Ltd TEVA reported second-quarter 2024 sales of $4.16 billion, beating the consensus of $4.06 billion.

Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales

Teva stock jumped early Wednesday after generic drugs helped drive a second-quarter beat. The company also raised its outlook.

Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise

Teva Pharmaceutical Industries raised its full-year profit forecast on Wednesday, banking on strength in its generic drug business and strong sales of its Huntington's disease drug.

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics

Teva Pharmaceutical's stock is up 69% since December, driven by legal resolution, blockbuster drugs, debt reduction, and new product launches. Recent developments include the launch of biosimilars and generics, positive data on Uzedy and Ajovy, and an accelerated timeline for TEV-48574. Financially, Teva's current ratio is under 1, with upcoming debt maturities posing a challenge. Recommendation remains "Hold" pending Q2 earnings.

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Sanofi

PARSIPPANY, N.J. & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Sanofi today announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-'574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for moderate-to-severe IBD. Patient enrollment in the RELIEVE UCCD (ulcerative colitis and Crohn's disease) Phase 2b trial has completed early due to significant.

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.

TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today positive topline results from its Phase 3 SPACE study evaluating the efficacy of AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years. The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo. Safety data was consistent wi.

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

Airbnb

Pinterest

There's never a bad time to put your money to work on Wall Street if you have a long-term mindset. A majority of online brokers have eliminated commission fees on common stock trades and minimum deposit requirements, which is great news for retail investors.

3 No-Brainer Stocks to Buy With $200 Right Now

Amphastar Pharma

Viatris

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year.

Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call wil.

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024

Teva Pharmaceuticals Industries Ltd.'s stock fell 2% Monday after a report said the Federal Trade Commission has opened an investigation into the Israeli generics company, citing its refusal to take down roughly two dozen patents for its asthma and COPD inhalers.

Teva's stock falls after report FTC has opened probe of patents

The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.

FTC starts probe into Teva about some products' patents, Washington Post reports

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use. The sub-analysis from the PEARL real world data explored the impact.

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Pharmaceutical Industries has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday.

Teva settles tax dispute in Israel with $750 mln payment

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end this historical income tax issue, and to continue to focus on its com.

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020

Novo Nordisk

Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States. “By launching an authorized generic for Victoza® (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Te.

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States

Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.

News for Teva Pharmaceutical Stock (TEVA)